Glenmark Pharma Gets US FDA Approval for Fluticasone Nasal Spray
Glenmark Pharmaceuticals received final U.S. FDA approval for its fluticasone propionate nasal spray USP (0.05 mg/spray), a direct generic equivalent to Haleon’s Flonase, giving it access to a $295.2 million market. The company reported 18.1% YoY domestic sales growth in Q1 FY27 and 19.8% YoY U.S. growth excluding out-licensing after launching nine products.